CLAIMS

1. Use of neridronic acid or a salt thereof for the manufacture of a medicament for the treatment of osteoarthritis, wherein the treatment of osteoarthritis comprises alleviating the pain symptomatology of joint pain.

2. The use of claim 1, wherein the treatment of osteoarthritis comprises alleviating joint stiffness and improving mobility and physical functionality.

3. The use of claim 1 or 2, wherein the treatment of osteoarthritis comprises reducing the size and extent of bone marrow lesions.

4. The use of any one of claims 1-3, wherein said salt of neridronic acid is sodium neridronate.

5. The use of any one of claims 1-4, wherein said neridronic acid or a salt thereof is to be administered at a dosage of 10-500 mg.

6. The use of any one of claims 1-5, wherein said neridronic acid or a salt thereof is to be administered orally, intramuscularly, intravenously, intraarticularly, transdermally, subcutaneously or topically.

7. The use of claim 6, wherein said neridronic acid or a salt thereof is to be administered intravenously.

8. The use of claim 7, wherein said neridronic acid or a salt thereof is to be administered intravenously at a dosage of 25-400 mg, at least 2 times, with at least 1 day between an administration and a subsequent one.

9. The use of claim 8, wherein said salt of neridronic acid is sodium neridronate to be administered intravenously at a dosage equivalent to 100 mg of neridronic acid, 4 times over a period of 10 days, with 3 days between an administration and a subsequent one.

10. The use of claim 9, wherein sodium neridronate is to be administered intravenously on days 1, 4, 7 and 10.

11. The use of any one of claims 1-10 comprising administering a pharmaceutical composition comprising neridronic acid or a salt thereof and pharmaceutically acceptable vehicles for oral, intramuscular, intravenous, intra-articular, transdermal, sub-cutaneous or topical administration.

12. The use of claim 11, wherein the pharmaceutical composition is to be administered intravenously, and comprises sodium neridronate, sodium chloride, citric acid and sodium citrate, or comprises sodium neridronate, sodium chloride, and sodium bicarbonate.

13. The use of claim 11 or 12, wherein the pharmaceutical composition is present as a unit dose comprising 1-10 ml of aqueous solution in a vial or bottle, said unit dose preferably comprising 70-150 mg of neridronic acid or a salt thereof.

14. The use of any one of claims 1-13, comprising a vial or bottle for intravenous administration comprising neridronic acid or a salt thereof.

15. The use of claim 14, wherein the vial or bottle comprises a unit dose of 70-150 mg of neridronic acid or a salt thereof.

16. The use of claim 15, wherein the vial or bottle comprises 100 mg of neridronic acid or comprising a salt thereof in an amount equivalent to 100 mg of neridronic acid.

17. The use of any one of claim 14-16, wherein said salt of neridronic acid is sodium neridronate.

18. The use of claim 6, wherein said neridronic acid or a salt thereof is administered intramuscularly.

19. The use of claim 18, wherein said neridronic acid or a salt thereof is administered intramuscularly at a dosage of 10-100 mg, preferably 15-50 mg.

20. The use of claim 19, wherein said salt of neridronic acid is sodium neridronate to be administered intramuscularly at a dosage equivalent to 25 mg of neridronic acid.